# Chemours Co (CC)

Informational only - not investment advice.

CIK: 0001627223
SIC: 2800 Chemicals & Allied Products
SIC breadcrumb: [Manufacturing](/division/D/) > [Chemicals And Allied Products](/major-group/28/) > [SIC 2800 Chemicals & Allied Products](/industry/2800/)
Latest 10-K filed: 2026-02-24
SEC page: https://www.sec.gov/edgar/browse/?CIK=1627223
Filing source: https://www.sec.gov/Archives/edgar/data/1627223/000119312526065201/cc-20251231.htm

## At a glance

FY2025 · period end 2025-12-31 · filed 2026-02-24 · accession 0001193125-26-065201 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001627223.json

| Metric | Value | FY | Provenance |
| --- | ---: | ---: | --- |
| Revenue | 5,808,000,000 USD | 2025 | verified |
| Net income | -386,000,000 USD | 2025 | verified |
| Assets | 7,382,000,000 USD | 2025 | verified |
| Free cash flow | 51,000,000 USD | 2025 | computed |
| Net margin | -6.65% | 2025 | computed |
| Revenue YoY | +0.45% | 2025 | computed |
| ROE | -154.40% | 2025 | computed |

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

### Peer percentile fingerprint

| Ratio | CC | Peer median | Percentile | N |
| --- | ---: | ---: | ---: | ---: |
| Net margin | -6.6% | -5.0% | 40 | 11 |
| Revenue growth | 0.4% | 0.4% | 50 | 11 |
| FCF margin | 0.9% | 3.7% | 20 | 11 |
| ROE | -154.4% | -10.3% | 10 | 11 |
| ROA | -5.2% | -4.0% | 40 | 11 |
| Liabilities / equity | 28.52 | 1.48 | 90 | 11 |
| Current ratio | 1.78 | 1.78 | 50 | 11 |

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 2800 Chemicals & Allied Products, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

## Selected Fundamentals
| Metric | Value | Unit | FY | Filed |
| --- | ---: | --- | ---: | --- |
| Revenue | 5808000000 | USD | 2025 | 2026-02-24 |
| Net income | -386000000 | USD | 2025 | 2026-02-24 |
| Assets | 7382000000 | USD | 2025 | 2026-02-24 |

## Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-02-24. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001627223.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | 5,400,000,000 | 6,183,000,000 | 6,638,000,000 | 5,526,000,000 | 4,969,000,000 | 6,345,000,000 | 6,831,000,000 | 6,078,000,000 | 5,782,000,000 | 5,808,000,000 |
| Net income | 7,000,000 | 746,000,000 | 995,000,000 | -52,000,000 | 219,000,000 | 608,000,000 | 578,000,000 | -253,000,000 | 69,000,000 | -386,000,000 |
| Gross profit | 1,103,000,000 | 1,745,000,000 | 1,971,000,000 | 1,063,000,000 | 1,067,000,000 | 1,381,000,000 | 1,616,000,000 | 1,302,000,000 | 1,142,000,000 | 902,000,000 |
| Diluted EPS | 0.04 | 3.91 | 5.45 | -0.32 | 1.32 | 3.60 | 3.65 | -1.70 | 0.46 | -2.57 |
| Operating cash flow | 594,000,000 | 640,000,000 | 1,140,000,000 | 650,000,000 | 807,000,000 | 814,000,000 | 755,000,000 | 556,000,000 | -633,000,000 | 264,000,000 |
| Capital expenditures | 338,000,000 | 411,000,000 | 498,000,000 | 481,000,000 | 267,000,000 | 277,000,000 | 307,000,000 | 370,000,000 | 360,000,000 | 213,000,000 |
| Dividends paid |  |  | 148,000,000 | 164,000,000 | 164,000,000 | 164,000,000 | 154,000,000 | 149,000,000 | 148,000,000 | 78,000,000 |
| Assets | 6,060,000,000 | 7,293,000,000 | 7,362,000,000 | 7,258,000,000 | 7,082,000,000 | 7,550,000,000 | 7,640,000,000 | 8,241,000,000 | 7,509,000,000 | 7,382,000,000 |
| Liabilities | 5,956,000,000 | 6,428,000,000 | 6,342,000,000 | 6,563,000,000 | 6,267,000,000 | 6,468,000,000 | 6,533,000,000 | 7,518,000,000 | 6,937,000,000 | 7,131,000,000 |
| Stockholders' equity | 100,000,000 | 860,000,000 | 1,014,000,000 | 689,000,000 | 813,000,000 | 1,081,000,000 | 1,107,000,000 | 721,000,000 | 571,000,000 | 250,000,000 |
| Cash and cash equivalents | 902,000,000 | 1,556,000,000 | 1,201,000,000 | 943,000,000 | 1,105,000,000 | 1,451,000,000 | 1,102,000,000 | 1,203,000,000 | 713,000,000 | 670,000,000 |
| Free cash flow | 256,000,000 | 229,000,000 | 642,000,000 | 169,000,000 | 540,000,000 | 537,000,000 | 448,000,000 | 186,000,000 | -993,000,000 | 51,000,000 |

### Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net margin | 0.13% | 12.07% | 14.99% | -0.94% | 4.41% | 9.58% | 8.46% | -4.16% | 1.19% | -6.65% |
| Return on equity | 7.00% | 86.74% | 98.13% | -7.55% | 26.94% | 56.24% | 52.21% | -35.09% | 12.08% | -154.40% |
| Return on assets | 0.12% | 10.23% | 13.52% | -0.72% | 3.09% | 8.05% | 7.57% | -3.07% | 0.92% | -5.23% |
| Liabilities / equity | 59.56 | 7.47 | 6.25 | 9.53 | 7.71 | 5.98 | 5.90 | 10.43 | 12.15 | 28.52 |
| Current ratio | 1.44 | 2.12 | 1.93 | 1.80 | 1.83 | 1.80 | 1.70 | 1.55 | 1.66 | 1.78 |

## As-reported value updates

4 tracked differences above grepcent's stated thresholds were found between the earliest XBRL-filed value and the value currently on file for the same fiscal period.

Ledger: /company/CC/revisions/


## Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-05. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001627223.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

| Quarter | End date | Revenue | Net income | Diluted EPS | Method |
| --- | --- | ---: | ---: | ---: | --- |
| 2022-Q3 | 2022-09-30 |  |  | 1.52 | reported discrete quarter |
| 2023-Q1 | 2023-03-31 |  |  | 0.96 | reported discrete quarter |
| 2023-Q2 | 2023-06-30 |  |  | -2.52 | reported discrete quarter |
| 2023-Q3 | 2023-09-30 | 1,487,000,000 | 20,000,000 | 0.13 | reported discrete quarter |
| 2023-Q4 | 2023-12-31 | 1,361,000,000 | -26,000,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2024-Q1 | 2024-03-31 | 1,350,000,000 | 52,000,000 | 0.34 | reported discrete quarter |
| 2024-Q2 | 2024-06-30 | 1,538,000,000 | 70,000,000 | 0.46 | reported discrete quarter |
| 2024-Q3 | 2024-09-30 | 1,501,000,000 | -27,000,000 | -0.18 | reported discrete quarter |
| 2024-Q4 | 2024-12-31 | 1,394,000,000 | -8,000,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2025-Q1 | 2025-03-31 | 1,368,000,000 | -4,000,000 | -0.03 | reported discrete quarter |
| 2025-Q2 | 2025-06-30 | 1,615,000,000 | -381,000,000 | -2.54 | reported discrete quarter |
| 2025-Q3 | 2025-09-30 | 1,495,000,000 | 60,000,000 | 0.40 | reported discrete quarter |
| 2025-Q4 | 2025-12-31 | 1,330,000,000 | -61,000,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2026-Q1 | 2026-03-31 | 1,381,000,000 | -29,000,000 | -0.19 | reported discrete quarter |
| 2026-Q2 | 2026-06-30 | 1,591,000,000 | -274,000,000 | -1.81 | reported discrete quarter |

## Filed narrative (10-K & 10-Q)

## Business

Verbatim Item 1 Business section from CC's latest 10-K: [/company/CC/business/](/company/CC/business/).

## Risk Factors

Verbatim Item 1A Risk Factors from CC's latest 10-K: [/company/CC/risk-factors/](/company/CC/risk-factors/).

## Latest quarter (10-Q)

Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/1627223/000162722326000024/cc-20260630.htm

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary.
Confidence: high
Filing date: 2026-08-05
Report date: 2026-06-30

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) supplements the unaudited Interim Consolidated Financial Statements and the related notes thereto included elsewhere herein to help provide an understanding of our financial condition, changes in our financial condition, and the results of our operations for the periods presented. Unless the context otherwise requires, references herein to “The Chemours Company”, “Chemours”, “the Company”, “our Company”, “we”, “us”, and “our” refer to The Chemours Company and its consolidated subsidiaries. References herein to “EID” refer to EIDP, Inc., formerly known as E. I. du Pont de Nemours and Company, which is our former parent company and is now a subsidiary of Corteva, Inc. (“Corteva”), a Delaware corporation. References herein to “DuPont” refer to DuPont de Nemours, Inc., a Delaware Corporation.

This MD&A should be read in conjunction with the unaudited Interim Consolidated Financial Statements and the related notes thereto included in Item 1 of this Quarterly Report on Form 10-Q, as well as our audited Consolidated Financial Statements and the related notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2025.

This section and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements, within the meaning of the federal securities laws, that involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. The words “believe”, “expect”, “anticipate”, “plan”, “estimate”, “target”, “project”, and similar expressions, among others, generally identify “forward-looking statements”, which speak only as of the date the statements were made. The matters discussed in these forward-looking statements are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those set forth in the forward-looking statements.

Our forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized. These statements, as well as our historical performance, are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond our control. Additionally, there may be other risks and uncertainties that we are unable to identify at this time or that we do not currently expect to have a material impact on our business. Factors that could cause or contribute to these differences include, but are not limited to, the risks, uncertainties, and other factors discussed in the Forward-looking Statements and the Risk Factors sections in our Annual Report on Form 10-K for the year ended December 31, 2025, and as otherwise discussed in this report. We assume no obligation to revise or update any forward-looking statement for any reason, except as required by law.

Overview

We are a leading, global provider of performance chemicals that are key inputs in end-products and processes in a variety of industries. We deliver customized solutions with a wide range of industrial and specialty chemical products for markets, including refrigeration and air conditioning, paints and coatings, plastics, transportation, semiconductor and consumer electronics, general industrial, and oil and gas. Our principal products include refrigerants, titanium dioxide (“TiO2”) pigment and industrial fluoropolymer resins. We manage and report our operating results through three principal reportable segments: Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials. Our Thermal & Specialized Solutions segment is a leading, global provider of refrigerants, thermal management solutions, propellants, blowing agents, and specialty solvents. Our Titanium Technologies segment is a leading, global provider of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, and protection in a variety of applications. Our Advanced Performance Materials segment is a leading, global provider of high-end polymers and advanced materials that deliver unique attributes, including low friction coefficients, extreme temperature resistance, weather resistance, ultraviolet and chemical resistance, and electrical insulation.

Our world-class product portfolio enables the performance and convenience of everyday products, processes, and technologies people rely on in their daily lives, making our products and the solutions they enable both vital and essential. We are committed to creating value for our customers and stakeholders by leveraging strengths that we use to create competitive advantage: our innovation and technical expertise, our ability to operate complex manufacturing sites safely, our deep customer relationships based on trust and reliability, and our talented workforce. Every day our people bring our chemistry to life, guided by five core values that form the bedrock foundation for how we operate: (i) Safety – we are committed to protecting people and the environment; (ii) Integrity – we do what's right; (iii) Partnership – we win through collaboration with the right internal and external partners; (iv) Ownership – we are each accountable for the Company's success; (v) Respect – we treat people well, include others, and value diverse perspectives.

Our core values, in unison with our company vision of Trusted Chemistry, helping people live better lives and communities thrive, underpin our commitment to our stakeholders. Our values and vision cannot be separated from our business strategy.

73

The Chemours Company

At Chemours, our approach to Sustainability begins with our vision to deliver Trusted Chemistry that helps people live better lives and communities to thrive. In 2018, we set forth ambitious Corporate Responsibility Commitment ("CRC") goals that we aim to achieve by 2030. These goals are designed to promote accountability and enable us to measure and transparently report the progress and impact of our sustainability commitment. Leveraging a robust governance framework, we are working to integrate sustainability across our organization and our business management processes. Our work in sustainability creates value for our shareholders by protecting our right to operate, meeting the needs of our customers, and advancing our corporate strategy, Pathway to Thrive. We understand that maintaining safe, sustainable operations has an impact on us, our communities, the environment, and our collective future. We deliver for our customers and society by designing sustainable offerings that perform at the highest level while minimizing impact on the environment. We are a leader in responsible manufacturing and we value partnership and collaboration to drive change. We are committed to continue working with policymakers, our value chain, and other organizations to find solutions that meet science-based regulations and address community needs.

Recent Developments

Tariffs

The chemicals sector has been and continues to be impacted by changes in U.S. and foreign trade policies, particularly the introduction and adjustment of tariffs by the United States as well as foreign retaliatory tariffs. We actively monitor changes and adjust our operations accordingly to enhance supply chain flexibility, including taking certain pricing actions and evaluating opportunities to source products not directly impacted by existing or potential tariffs. After the U.S. Supreme Court ruled in February 2026 that the International Emergency Economic Powers Act (“IEEPA”) does not authorize the President of the United States (the “President”) to impose tariffs, U.S. Customs and Border Protection established a process to return paid IEEPA tariffs to importers. The Company began receiving IEEPA refunds during the second quarter of 2026. In July 2026, the President imposed additional tariffs under Section 301 of the Trade Act of 1974 and Section 338 of the Tariff Act of 1930, which apply to the vast majority of U.S. imports. The President also has imposed additional tariffs on certain products under Section 232 of the Trade Expansion Act of 1962. The long-term impact of tariffs, including potential changes to existing tariffs or the imposition of further retaliatory trade measures, as well as possible tariff refunds, on our business, financial condition and results of operations remains uncertain.

74

The Chemours Company

Results of Operations and Business Highlights

Results of Operations

The following table sets forth our results of operations for the three and six months ended June 30, 2026 and 2025.

[[GREPCENT_TABLE]]
[["","","Three Months Ended June 30,","","","Six Months Ended June 30,"],["(Dollars in millions, except per share amounts)","","2026","","","2025","","","2026","","","2025"],["Net sales","","$","1,591","","","$","1,615","","","$","2,972","","","$","2,983"],["Cost of goods sold","","","1,305","","","","1,337","","","","2,474","","","","2,469"],["Gross profit","","","286","","","","278","","","","498","","","","514"],["Selling, general, and administrative expense","","","469","","","","424","","","","616","","","","547"],["Research and development expense","","","27","","","","28","","","","53","","","","55"],["Restructuring, asset-related, and other charges","","","3","","","","18","","","","16","","","","51"],["Total other operating expenses","","","499","","","","470","","","","685","","","","653"],["Equity in earnings of affiliates","","","9","","","","9","","","","17","","","","17"],["Interest expense, net","","","(68",")","","","(67",")","","","(137",")","","","(133",")"],["Loss on extinguishment of debt","","","(2",")","","","\u2014","","","","(11",")","","","\u2014"],["Other income, net","","","273","","","","2","","","","296","","","","6"],["Loss before income taxes","","","(1",")","","","(248",")","","","(22",")","","","(249",")"],["Provision for income taxes","","","273","","","","131","","","","281","","","","135"],["Net loss","","","(274",")","","","(379",")","","","(303",")","","","(384",")"],["Less: Net income attributable to non-controlling interests","","","\u2014","","","","1","","","","\u2014","","","","1"],["Net loss attributable to Chemours","","$","(274",")","","$","(380",")","","$","(303",")","","$","(385",")"],["Per share data"],["Basic (loss) earnings per share of common stock","","$","(1.81",")","","$","(2.53",")","","$","(2.01",")","","$","(2.56",")"],["Diluted (loss) earnings per share of common stock","","","(1.81",")","","","(2.53",")","","","(2.01",")","","","(2.56",")"]]
[[/GREPCENT_TABLE]]

75

The Chemours Company

Net Sales

The following table sets forth the impacts of price, volume, currency, and portfolio changes on our net sales for the three and six months ended June 30, 2026.

[[GREPCENT_TABLE]]
[["Change in net sales from prior period","","Three Months Ended June 30, 2026","","","Six Months Ended June 30, 2026"],["Price","","","2","%","","","2","%"],["Volume","","","(4",")%","","","(4",")%"],["Currency","","","1","%","","","2","%"],["Portfolio","","","\u2014","%","","","\u2014","%"],["Total change in net sales","","","(1",")%","","","\u2014","%"]]
[[/GREPCENT_TABLE]]

Our net sales were relatively flat at $1.6 billion for the three months ended June 30, 2026 and 2025, as a decrease in volume of 4% was offset by an increase in price of 2% and favorable currency movements of 1%. The decrease in volume was primarily driven by lower volumes in Thermal & Specialized Solutions ("TSS") and Advanced Performance Materials ("APM") segments, while the increase in price was attributable to our TSS and Titanium Technologies ("TT") segments.

Our net sales were relatively flat at $3 billion for the six months

[Excerpt truncated for page length; source filing is linked above.]

## Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/1627223/000119312526065201/cc-20251231.htm
Complete FY 2025 MD&A: /company/CC/mda/fy2025/

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary.
Confidence: high
Filing date: 2026-02-24
Report date: 2025-12-31

Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) supplements the Consolidated Financial Statements and the related notes thereto included elsewhere herein to help provide an understanding of our financial condition, changes in our financial condition, and the results of our operations for the periods presented. For the year ended December 31, 2023, and changes from the year ended December 31, 2023 to the year ended December 31, 2024, management’s discussion and analysis pertaining to our financial condition, changes in our financial condition, and the results of our operations have been omitted from this MD&A and may be found in Item 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations as included in our Annual Report on Form 10-K for the year ended December 31, 2024. This MD&A should be read in conjunction with the Consolidated Financial Statements and the related notes thereto included elsewhere in this Annual Report on Form 10-K.

Our forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized. These statements, as well as our historical performance, are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond our control. Additionally, there may be other risks and uncertainties that we are unable to identify at this time or that we do not currently expect to have a material impact on our business. Factors that could cause or contribute to these differences include, but are not limited to, the risks, uncertainties, and other factors discussed within Item 1A – Risk Factors in this Annual Report on Form 10-K.

Overview

We are a leading, global provider of performance chemicals that are key inputs in end-products and processes in a variety of industries. We deliver customized solutions with a wide range of industrial and specialty chemical products for markets, including refrigeration and air conditioning, paints and coatings, plastics, transportation, semiconductor and consumer electronics, general industrial, and oil and gas. Our principal products include refrigerants, titanium dioxide ("TiO2") pigment and industrial fluoropolymer resins. We manage and report our operating results through three principal reportable segments: Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials. Our Thermal & Specialized Solutions segment is a leading, global provider of refrigerants, thermal management solutions, propellants, blowing agents, and specialty solvents. Our Titanium Technologies segment is a leading, global provider of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, and protection in a variety of applications. Our Advanced Performance Materials segment is a leading, global provider of high-end polymers and advanced materials that deliver unique attributes, including low friction coefficients, extreme temperature resistance, weather resistance, ultraviolet and chemical resistance, and electrical insulation. Our Performance Chemicals and Intermediates business is presented under Other Segment.

Recent Developments

Sale of Former Taiwan Titanium Technologies Site

In January 2026, we, through our subsidiary, The Chemours (Taiwan) Company Limited, entered into the Purchase Agreements with four entities affiliated with each other: Century Wind Power Co., Ltd., Century Iron and Steel Industrial Co., Ltd., Century Huaxin Wind Energy Co., Ltd. and Mr. Lai Wen-Hsiang, to sell ten parcels of land in Kuan Yin, Taiwan, for a total purchase price of approximately $360 million. We anticipate that the sale of the Property will be completed through one or more closings, which are expected to occur by mid-year 2026, subject to the satisfaction of certain closing conditions set forth in the Purchase Agreements and local regulatory approval, inclusive of environmental conditions. We intend to use the cash proceeds from the sale of the Property to reduce the Company’s debt obligations.

Washington Works Operational Disruption

In January 2026, our Washington Works site experienced a disruption that necessitated a temporary shutdown, limiting our capacity at this key manufacturing facility in our Advanced Performance Materials business. This event was traced to equipment affected by a local utility service outage in August of 2025, which is integral to our fluoropolymer supply chain and involves complex chemical processing technology. Although operations have resumed, the unplanned outage coincided with challenging winter weather, resulting in delays to the restart. This unplanned outage is expected to have a negative earnings impact of $20 million to $25 million for APM in the first quarter of 2026.

44

The Chemours Company

Titanium Technologies Updates

As part of our Portfolio Management pillar of our Pathway to Thrive Strategy, in January 2026, we made the strategic decision to temporarily idle one of our mines located in northern Florida and transition to a third-party earth-moving contractor. This revised approach is expected to support our overall cost efforts and promote improved cash generation. Also in our Titanium Technologies business, in February 2026, we welcomed Michael Foley as the new business president.

Amendment to Amended and Restated Credit Agreement

On October 15, 2025, we entered into Amendment No. 4 (the “Fourth Amendment”) among the Company, certain subsidiaries of the Company, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent, which amends the Credit Agreement. The Fourth Amendment extended the maturity date of our $1,050 million senior secured U.S. Dollar Term Loan from August 18, 2028 to October 15, 2032. The Fourth Amendment also changed the applicable margin in respect of the Dollar Term Loan to, at our election, adjusted Term Secured Overnight Financing Rate ("SOFR") + 3.50% or adjusted base rate plus 2.50%.

European Accounts Receivable Factoring Arrangement

On October 13, 2025, we entered into a Receivables Purchase Agreement (the "Purchase Agreement") with BNP Paribas Factor GmbH (“BNP”). Pursuant to the Purchase Agreement, and subject to the terms and conditions set forth therein, certain subsidiaries of the Company agreed to offer for sale and to sell, and BNP agreed to purchase, certain eligible receivables and related rights in an amount of up to an aggregate outstanding balance of €180 million. The initial term of the Purchase Agreement extends through October 31, 2026 and will be automatically extended for one-year period, unless earlier terminated in accordance with the terms of the Purchase Agreement.

Tariffs

The chemicals sector has been and continues to be impacted by changes in U.S. and foreign trade policies, particularly the introduction and adjustment of tariffs by the United States as well as foreign retaliatory tariffs. We actively monitor changes and adjust our operations accordingly to enhance supply chain flexibility, including taking certain pricing actions and evaluating opportunities to source products not directly impacted by existing or potential tariffs. The long-term impact of tariffs, including potential changes to existing tariffs or the imposition of further retaliatory trade measures, on our business, financial condition and results of operations remains uncertain.

45

The Chemours Company

Results of Operations and Business Highlights

Results of Operations

The following table sets forth our results of operations for the years ended December 31, 2025 and 2024.

[[GREPCENT_TABLE]]
[["","","Year Ended December 31,"],["(Dollars in millions, except per share amounts)","","2025","","","2024"],["Net sales","","$","5,808","","","$","5,782"],["Cost of goods sold","","","4,906","","","","4,640"],["Gross profit","","","902","","","","1,142"],["Selling, general, and administrative expense","","","799","","","","598"],["Research and development expense","","","108","","","","109"],["Restructuring, asset-related, and other charges","","","59","","","","60"],["Goodwill impairment charge","","","\u2014","","","","56"],["Total other operating expenses","","","966","","","","823"],["Equity in earnings of affiliates","","","35","","","","43"],["Interest expense, net","","","(269",")","","","(263",")"],["Loss on extinguishment of debt","","","(5",")","","","(1",")"],["Other income, net","","","26","","","","8"],["(Loss) income before income taxes","","","(277",")","","","106"],["Provision for income taxes","","","109","","","","37"],["Net (loss) income","","","(386",")","","","69"],["Less: Net income attributable to non-controlling interests","","","\u2014","","","","\u2014"],["Net (loss) income attributable to Chemours","","$","(386",")","","$","69"],["Per share data"],["Basic (loss) earnings per share of common stock","","$","(2.57",")","","$","0.46"],["Diluted (loss) earnings per share of common stock","","","(2.57",")","","","0.46"]]
[[/GREPCENT_TABLE]]

Net Sales

The following table sets forth the impacts of price, volume, currency, and portfolio changes on our net sales for the year ended December 31, 2025.

[[GREPCENT_TABLE]]
[["Change in net sales from prior period","","Year Ended December 31, 2025"],["Price","","","\u2014","%"],["Volume","","","\u2014","%"],["Currency","","","\u2014","%"],["Portfolio","","","\u2014","%"],["Total change in net sales","","","\u2014","%"]]
[[/GREPCENT_TABLE]]

Our net sales increased by $26 million (or 0%) to $5.8 billion for the year ended December 31, 2025, compared with net sales of $5.8 billion for the same period in 2024. The increase in our net sales for the year ended December 31, 2025 was primarily attributable to a $236 million increase in our Thermal & Specialized Solutions segment net sales, partially offset by a $143 million and $63 million decrease in our Titanium Technologies and Advance Performance Materials segment net sales, respectively.

The drivers of these changes for each of our reportable segments are discussed further under the “Segment Reviews” section within this MD&A.

Cost of Goods Sold

Our cost of goods sold (“COGS”) increased by $266 million (or 6%) to $4.9 billion for the year ended December 31, 2025, compared with COGS of $4.6 billion for the same period in 2024. The increase in our COGS for the year ended December 31, 2025 was primarily attributable to higher raw materials costs.

46

The Chemours Company

Selling, General, and Administrative Expense

Our selling, general, and administrative (“SG&A”) expense increased by $201 million (or 34%) to $799 million for the year ended December 31, 2025, compared with SG&A expense of $598 million for the same period in 2024. The increase in our SG&A expense was primarily attributable to the litigation-related charges of $270 million associated with the settlement agreement with the State of New Jersey (as described in "Note 22 - Commitments and Contingent Liabilities) partially offset by an approximately $15 million decrease in consultant spending, a $15 million decrease in IT expenses, approximately $20 million of lower costs incurred related to the audit committee internal review and approximately $15 million of lower third-party costs related to the Titanium Technologies Transformation Plan.

Research and Development Expense

Our research and development (“R&D”) expense was relatively flat at $108 million for the year ended December 31, 2025, compared with R&D expense of $109 million for the year ended December 31, 2024.

Restructuring, Asset-related, and Other Charges

Our restructuring, asset-related, and other charges decreased by $1 million (or 2%) to $59 million for the year ended December 31, 2025, compared with $60 million for the same period in 2024.

For the year ended December

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A: /company/CC/mda/fy2025/
All MD&A years: /company/CC/mda/


## MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

- [FY 2024 MD&A](/company/CC/mda/fy2024/): filed 2025-02-18; accession 0000950170-25-021787 (https://www.sec.gov/Archives/edgar/data/1627223/000095017025021787/cc-20241231.htm)
- [FY 2023 MD&A](/company/CC/mda/fy2023/): filed 2024-03-27; accession 0000950170-24-037171 (https://www.sec.gov/Archives/edgar/data/1627223/000095017024037171/cc-20231231.htm)
- [FY 2022 MD&A](/company/CC/mda/fy2022/): filed 2023-02-10; accession 0000950170-23-002467 (https://www.sec.gov/Archives/edgar/data/1627223/000095017023002467/cc-20221231.htm)
- [FY 2021 MD&A](/company/CC/mda/fy2021/): filed 2022-02-11; accession 0001564590-22-004791 (https://www.sec.gov/Archives/edgar/data/1627223/000156459022004791/cc-10k_20211231.htm)




## Macro cross-references

Indicators mapped to this company's SIC classification (industry 2800 Chemicals & Allied Products) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

- [INDPRO](/indicator/INDPRO/): Industrial Production: Total Index
- [TCU](/indicator/TCU/): Capacity Utilization: Total Index
- [PPIACO](/indicator/PPIACO/): Producer Price Index by Commodity: All Commodities
- [GDPC1](/indicator/GDPC1/): Real Gross Domestic Product
- [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity
- [FEDFUNDS](/indicator/FEDFUNDS/): Federal Funds Effective Rate
- [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private
- [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm

Macro-to-micro threads including this sector: [Inflation (CPI / PCE / PPI)](/thread/inflation-cpi-pce-ppi/), [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Money & trade](/thread/money-trade/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/), [Industrial orders & inventories](/thread/industrial-orders/), [Trade & external](/thread/trade-external/).

All macro indicators: /indicators/


## For LLMs & downloads

Markdown twin: /company/CC.md · JSON record: /company/CC.json · verified financials: /company/CC/financials.json / /company/CC/financials.csv · machine TOC for the whole site: /llms.txt